Evercore ISI raised the firm’s price target on Health Catalyst to $10 from $8 and keeps an Outperform rating on the shares. The firm is adjusting estimates and making additions to Evercore’s “Tactical Outperform” and “Tactical Underperform” lists ahead of Q3 earnings from the Healthcare Technology and Distribution group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target raised to $13 from $10 at JPMorgan
- Health Catalyst price target lowered to $11 from $14 at Piper Sandler